Nanobiotix radiographic data shows high response rates in lung cancer trial
Nanobiotix (NASDAQ:NBTX) announced promising preliminary efficacy and safety data from Part 1 of the ongoing CONVERGE study at the 2026 European Society for Radiotherapy and Oncology (ESTRO) Annual Meeting.
The randomized Phase 2 clinical trial, sponsored by Johnson & Johnson, is evaluating JNJ-1900 (also known as NBTXR3), a potential first-in-class intratumoral nanoradioenhancer designed to amplify the efficacy of radiotherapy in patients with Stage 3 inoperable non-small cell lung cancer (NSCLC).
The data indicated that intratumoral or intranodal injection of JNJ-1900 is clinically feasible and can be safely administered within the trial cohort.
Initial efficacy outcomes tracked across seven patients who completed the full therapeutic regimen—consisting of concurrent chemoradiotherapy, JNJ-1900, and consolidation therapy with the checkpoint inhibitor durvalumab—yielded an overall response rate (ORR) of 85.7% (six out of seven patients).
Notably, the complete response rate (CRR) reached 57.1% (four out of seven patients).
This marks a significant departure from the current standard of care—concurrent chemoradiation therapy with or without durvalumab—where the historical depth of response remains limited and the complete response rate is typically below 5%.
The study also achieved a disease control rate (DCR) of 100%, with investigators reporting an absence of progressive disease and a deepening of therapeutic response over time, suggesting potential long-term durability for the combination treatment.
